Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Standard Specimen Reference Set: Colon

Standard Specimen Reference Set: Colon

251
Brenner, DeanUniversity of Michigan

No involved investigator sites defined.

N/A
Other, Specify
G.I. and Other Associated Cancers Research Group

The Early Detection Research Network, Great Lakes-New England Clinical, Epidemiological and Validation Center (GLNE CVC) announces the availability of serum, plasma and urine samples for the early detection for colon cancer and validation studies.

Two prospective studies were used to collect samples to make this reference set. GLNE 001, (Preliminary Clinical Characterization of Serum, Plasma, and Urine Biomarkers for Colorectal Neoplasms) was a prospective, cross-sectional clinical trial to collect serum, plasma, urine, and common data elements on subjects undergoing routine screening colonoscopy or subjects undergoing surgery or endoscopy for colon cancer. GLNE 007 (Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas) is an on-going prospective, cross-sectional clinical to collect serum, plasma, urine, stool, and common data elements. In both protocols, subjects were undergoing routine colonoscopy (or being seen in surgery clinic for colorectal cancer) when the samples were collected. Samples were collected while the target lesions were still in place in the colon. Subjects were either normal (without adenomas or cancer), with pathologically confirmed adenomas or pathologically confirmed colorectal adenocarcinoma. Exclusion criteria for both protocols included known hepatitis C or HIV, ulcerative colitis, Crohns’s Disease or IBD, history of cancer within 3 years, or genetic colon diseases including FAP or HNPCC. Samples were collected from 4 sites around North America.
N/A

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


New Funding Opportunity: Biomarker Development Laboratories for the Early Detection Network: Applications Due May 23

Update: Pre-application webinar information now available.

The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.

The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.

The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.